切换至 "中华医学电子期刊资源库"
高级检索
中华脑血管病杂志(电子版)

中华脑血管病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 188 -192. doi: 10.11817/j.issn.1673-9248.2022.03.008

论著

心房颤动患者导管射频消融术后复发的危险因素及血小板与淋巴细胞比值对术后复发的诊断价值
张智文1, 雷志博1, 李牧蔚1,†(), 黄改荣1, 王山岭1, 刘静静1, 王婷1, 赵丹清1, 杨海涛1   
  1. 1. 450003　郑州，郑州大学人民医院（河南省人民医院）心血管内科
  • 收稿日期:2021-09-15 出版日期:2022-06-01
  • 通信作者: 李牧蔚
  • 基金资助:
    河南省自然科学基金(202300410465); 河南省医学科技攻关计划项目(LHGJ20190784)

Clinical significance of platelet to lymphocyte ratio in evaluating the recurrence of radiofrequency ablation in patients with atrial fibrillation

Zhiwen Zhang1, Zhibo Lei1, Muwei Li1,†(), Gairong Huang1, Shanling Wang1, Jingjing Liu1, Ting Wang1, Danqing Zhao1, Haitao Yang1   

  1. 1. Department of Cardiology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou 450003, China
  • Received:2021-09-15 Published:2022-06-01
  • Corresponding author: Muwei Li
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张智文, 雷志博, 李牧蔚, 黄改荣, 王山岭, 刘静静, 王婷, 赵丹清, 杨海涛. 心房颤动患者导管射频消融术后复发的危险因素及血小板与淋巴细胞比值对术后复发的诊断价值[J/OL]. 中华脑血管病杂志(电子版), 2022, 16(03): 188-192.

Zhiwen Zhang, Zhibo Lei, Muwei Li, Gairong Huang, Shanling Wang, Jingjing Liu, Ting Wang, Danqing Zhao, Haitao Yang. Clinical significance of platelet to lymphocyte ratio in evaluating the recurrence of radiofrequency ablation in patients with atrial fibrillation[J/OL]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(03): 188-192.

目的

探讨心房颤动（简称房颤）患者射频导管消融术（RFCA）后复发的危险因素及血小板与淋巴细胞比值（PLR）对术后复发的诊断价值。

方法

纳入2013年1月至2018年1月于河南省人民医院接受RFCA的312例房颤患者。按照患者术后3个月是否复发房颤，分为复发组（85例）和未复发组（227例），分析2组患者的一般临床资料、实验室检查指标和超声心动图指标，采用Logistic回归分析RFCA后房颤复发的危险因素，采用受试者工作特征（ROC）曲线评价PLR预测RFCA后房颤复发的价值；按照患者PLR中位数，将患者分为高PLR组（156例）和低PLR组（156例），并使用Kaplan-Meier生存曲线分析2组患者的预后。

结果

单因素分析结果显示，年龄、房颤病程、房颤类型、超敏C反应蛋白（hs-CRP）、中性粒细胞、血小板、淋巴细胞、PLR及左心房内径对房颤患者RFCA术后房颤有一定影响（P＜0.05）。多因素Logistic回归分析显示，年龄（OR=1.047）、持续性房颤（OR=2.519）、hs-CRP（OR=2.249）、血小板（OR=1.023）、PLR（OR=1.030）及左心房内径（OR=1.224）是RFCA术后房颤复发的独立危险因素（P＜0.05），淋巴细胞（OR=0.255）是RFCA后房颤复发的保护因素（P＜0.05）。ROC曲线结果显示，PLR预测RFCA术后房颤复发的曲线下面积为0.725（95%CI：0.672~0.774，P＜0.001）。Kaplan-Meier生存曲线结果显示高PLR组RFCA术后的房颤复发率明显高于低PLR组（P＜0.001）。

结论

房颤患者PLR水平与RFCA术后房颤复发密切相关，高PLR水平可作为预测房颤复发的信号，临床应加强PLR监测以及时评估患者的预后。

关键词: 血小板/淋巴细胞比值, 炎性反应, 心房颤动, 射频消融术, 复发
Objective

To investigate the clinical significance of platelet to lymphocyte ratio (PLR) in evaluating the recurrence of patients with atrial fibrillation (AF) after radiofrequency catheter ablation (RFCA).

Methods

Totally 312 patients with AF who received RFCA in Henan Provincial People’s Hospital from January 2013 to January 2018 were included. Patients were divided into recurrence group (n=85) and non-recurrence group (n=227) according to whether AF reoccurred 3 months after ablation. The general clinical data, laboratory indexes and echocardiography indexes of the two groups were analyzed. Logistic regression was used to analyze the related factors of AF recurrence after RFCA, and receiver operating characteristic (ROC) curve was used to evaluate the value of PLR in predicting the recurrence of AF after RFCA. The patients were divided into high PLR group (n=156) and low PLR group (n=156) according to the median PLR, and Kaplan-Meier survival curve was used to analyze the prognosis.

Results

Univariate analysis showed that age, course of atrial fibrillation, type of atrial fibrillation, high-sensitivity C-reactive protein (hs-CRP), neutrophils, platelets (PLT), lymphocytes, PLR, and left atrial diameter (LAD) had a positive effect on the AF recurrence after RFCA (P＜0.05). Multiple Logistic regression showed that age (OR=1.047), persistent atrial fibrillation (OR=2.519), hs-CRP (OR=2.249), PLT (OR=1.023), PLR (OR=1.030) and LAD (OR=1.224) were the independent risk factors for recurrence of AF recurrence after RFCA (P＜0.05), lymphocyte (OR=0.255) was protective factor for recurrence of AF recurrence after RFCA (P＜0.05). ROC curve showed that area under curve (AUC) predicted by PLR for AF recurrence after RFCA was 0.725（95%CI：0.672-0.774，P＜0.001）. The results of Kaplan-Meier survival curve showed that the recurrence of AF in high PLR group was significantly higher than that in low PLR group (P＜0.001).

Conclusion

The level of PLR is closely related to the recurrence of AF after RFCA. The high level of PLR can be used as a signal to predict the recurrence of AF. Clinical monitoring of PLR should be strengthened to evaluate the prognosis of patients in a timely manner.

Key words: Platelet/lymphocyte ratio, Inflammatory reaction, Atrial fibrillation, Radiofrequency catheter ablation, Recrudesce
表1 复发组与未复发组之间基线及临床指标比较
指标

复发组

（n=85）

未复发组

（n=227）

 统计值 P值
性别男/女，[例] 52/33 148/79 χ2=0.435 0.510
年龄（岁，
x¯
±s）		 57.4±10.7 52.6±10.5 t=2.582 0.001
抽烟[例（%）] 12（14.1） 45（19.8） χ2=1.349 0.246
饮酒[例（%）] 13（15.3） 40（17.6） χ2=0.237 0.625
高血压[例（%）] 37（43.5） 84（37.0） χ2=1.109 0.292
冠心病[例（%）] 11（12.9） 22（9.7） χ2=0.690 0.406
糖尿病[例（%）] 18（21.2） 34（15.0） χ2=1.711 0.191
血脂异常[例（%）] 30（35.3） 61（26.9） χ2=2.123 0.145
体质量指数（kg/m2,
x¯
±s）		 24.2±3.1 25.1±3.8 t=1.190 0.236
房颤病程[年，例（%）] χ2=10.569 0.001
≥1 32（37.6） 45（19.8）
＜1 53（62.4） 182（80.2）
房颤类型[例（%）] χ2=15.890 ＜0.001
阵发性房颤 35（41.2） 150（66.1）
持续性房颤 50（58.8） 77（33.9）
hs-CRP（mg/L，
x¯
±s）		 3.8±0.8 3.2±0.9 t=5.412 ＜0.001
中性粒细胞（×109/L,
x¯
±s）		 5.1±0.9 4.9±0.8 t=2.063 0.040
PLT（×109/L,
x¯
±s）		 257.1±30.6 234.3±32.2 t=5.647 ＜0.001
淋巴细胞（×109/L,
x¯
±s）		 1.9±0.5 2.1±0.4 t=-3.734 ＜0.001
PLR（
x¯
±s）		 135.8±25.2 114.6±26.1 t=6.463 ＜0.001
LAD（mm,
x¯
±s）		 42.3±4.1 39.8±3.4 t=5.169 ＜0.001
LVEDD（mm,
x¯
±s）		 44.8±5.3 46.1±6.1 t=-1.849 0.066
LVEF（%,
x¯
±s）		 57.5±8.7 59.2±8.6 t=-1.550 0.122
治疗药物[例（%）]
ACEI/ARB 23（27.1） 74（32.6） χ2=0.886 0.347
CCB 17（20.0） 50（22.0） χ2=0.151 0.698
β受体阻滞剂[例（%）] 46（54.1） 147（64.8） χ2=2.967 0.085
胺碘酮[例（%）] 22（25.9） 77（33.9） χ2=1.845 0.174
表2 经导管射频消融术后房颤复发的多因素Logistic回归分析
变量 β值 SE值 Wald χ2值 OR值 95%CI P值
年龄 0.046 0.017 6.925 1.047 1.012~1.083 0.008
房颤病程 0.535 0.366 2.143 1.708 0.834~3.496 0.143
持续性房颤 0.924 0.341 7.331 2.519 1.291~4.918 0.007
hs-CRP 0.810 0.218 13.829 2.249 1.467~3.446 ＜0.001
中性粒细胞 0.293 0.192 2.337 1.340 0.921~1.951 0.126
PLT 0.023 0.006 15.684 1.023 1.012~1.035 ＜0.001
淋巴细胞 -1.366 0.416 10.798 0.255 0.113~0.576 0.001
PLR 0.030 0.007 19.764 1.030 1.017~1.044 ＜0.001
LAD 0.202 0.048 17.996 1.224 1.115~1.343 ＜0.001
图1 血小板与淋巴细胞比值预测经导管射频消融术后复发的受试者操作特征曲线
图2 高PLR组与低PLR组的Kaplan-Meier生存曲线比较注：PLR为血小板与淋巴细胞比值，在该生存曲线中生存概率代表房颤未复发的概率
1
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association [J]. Eur Heart J, 2012, 33(21): 2719-2747.
2
黄从新, 张澍, 黄德嘉, 等. 心房颤动: 目前的认识和治疗建议(2018) [J]. 中华心律失常学杂志, 2018, 22(4): 279-346.
3
Zhang XY, Yu RH, Dong JZ. Clinical characteristics and efficacy of radiofrequency catheter ablation in the treatment of elderly patients with atrial fibrillation [J]. Am J Med Sci, 2017, 355(4): 357-361.
4
Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design [J]. Heart Rhythm, 2012, 9(4): 632-696.
5
Pallisgaard JL, Gislason GH, Hansen J, et al. Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study [J]. Eur Heart J, 2018, 39(6): 442-449.
6
Van Wagoner DR, Chung MK. Inflammation, inflammasome activation, and atrial fibrillation [J]. Circulation, 2018, 138(20): 2243-2246.
7
Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events [J]. Platelets, 2015, 26(7): 680-681.
8
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the Heart Rhythm Society [J]. J Am Coll Cardiol, 2014, 130(23): 2071-2104.
9
Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation [J]. N Engl J Med, 2016, 374(23): 2235-2245.
10
Ciuffo L, Tao S, Ipek E G, et al. Intra-atrial dyssynchrony during sinus rhythm predicts recurrence after the first catheter ablation for atrial fibrillation [J]. JACC Cardiovasc Imaging, 2018, 12(2): 310-319.
11
Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study [J]. Lancet, 2015, 386(9989): 154-162.
12
Wolowacz SE, Samuel M, Brennan VK, et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature [J]. Europace, 2011, 13(10): 1375-1385.
13
Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: an update [J]. Eur Heart J, 2014, 35(36): 2454-2459.
14
Kornej J, Schumacher K, Sommer P, et al. Very late arrhythmia recurrences in patients with sinus rhythm within the first year after catheter ablation: the Leipzig heart center AF ablation registry [J]. Europace, 2019, 21(11): 1646-1652.
15
Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by selayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study [J]. JAMA, 2014, 311(5): 498-506.
16
Köroğlu S, Tuncer C, Acar G, et al. Relation of inflammatory and oxidative markers to the occurrence and recurrence of persistent atrial fibrillation [J]. Turk Kardiyol Dern Ars, 2012, 40(6): 499-504.
17
Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation [J]. Circulation, 1997, 96(4): 1180-1184.
18
Hu YF, Chen YJ, Lin YJ, et al. Inflammation and the pathogenesis of atrial fibrillation [J]. Nat Rev Cardiol, 2015, 12(4): 230-243.
19
Kurtul A, Murat SN, Yarlioglues M,et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes [J]. J Am Coll Cardiol, 2014, 114(7): 972-978.
20
Gary T, Pichler M, Belaj K, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients [J]. PLoS One, 2013, 8(7): e67688.
21
Gungor H, Babu AS, Zencir C, et al. Association of preoperative platelet-to-lymphocyte ratio with atrial fibrillation after coronary artery bypass graft surgery [J]. Med Princ Pract, 2017, 26(2): 164-168.
[1] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[2] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[3] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径＜1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[4] 谢田伟, 庞于樊, 吴丽. 超声引导下不同消融术对甲状腺良性结节体积缩减率、复发率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 80-83.
[5] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[6] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[7] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[8] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[9] 闫亚飞, 范学圣, 张舰, 吴勇. 经腹腹膜前疝修补术治疗复发腹股沟疝的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 552-556.
[10] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[11] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[12] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[13] 杭丽, 张耀辉, 孙文恺. 参菝抗瘤液对结直肠腺瘤性息肉术后肠道功能、炎症指标及复发情况的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 413-416.
[14] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
[15] 郑屹, 刘莹, 张煜坤, 李广平, 陈康寅, 刘彤. 既往及新发心房颤动对急性心肌梗死患者远期卒中风险的影响[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 406-417.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号